IN163129B - - Google Patents

Info

Publication number
IN163129B
IN163129B IN921/MAS/86A IN921MA1986A IN163129B IN 163129 B IN163129 B IN 163129B IN 921MA1986 A IN921MA1986 A IN 921MA1986A IN 163129 B IN163129 B IN 163129B
Authority
IN
India
Application number
IN921/MAS/86A
Other languages
English (en)
Inventor
James Edward Jeffery
Derek Whybrow
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN163129(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of IN163129B publication Critical patent/IN163129B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IN921/MAS/86A 1985-12-17 1986-11-28 IN163129B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (1)

Publication Number Publication Date
IN163129B true IN163129B (en:Method) 1988-08-13

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
IN921/MAS/86A IN163129B (en:Method) 1985-12-17 1986-11-28

Country Status (34)

Country Link
US (2) US4929629A (en:Method)
EP (1) EP0230742B1 (en:Method)
JP (1) JPS62155240A (en:Method)
KR (1) KR940008913B1 (en:Method)
CN (1) CN1016245B (en:Method)
AT (1) ATE56942T1 (en:Method)
AU (1) AU601167B2 (en:Method)
CA (1) CA1266278A (en:Method)
CS (1) CS259545B2 (en:Method)
DD (1) DD263050A5 (en:Method)
DE (1) DE3674570D1 (en:Method)
DK (1) DK170770B1 (en:Method)
EG (1) EG17770A (en:Method)
ES (1) ES2018163T4 (en:Method)
FI (1) FI90413C (en:Method)
GB (1) GB8531071D0 (en:Method)
GE (1) GEP19970812B (en:Method)
GR (1) GR3001069T3 (en:Method)
HU (1) HU201901B (en:Method)
IE (1) IE59429B1 (en:Method)
IL (1) IL80934A (en:Method)
IN (1) IN163129B (en:Method)
LU (1) LU90865I2 (en:Method)
MX (1) MX4684A (en:Method)
NL (1) NL300065I1 (en:Method)
NO (2) NO165540C (en:Method)
NZ (1) NZ218578A (en:Method)
PH (1) PH22481A (en:Method)
PL (1) PL149519B1 (en:Method)
PT (1) PT83958B (en:Method)
SU (1) SU1443796A3 (en:Method)
UA (1) UA7206A1 (en:Method)
YU (1) YU46033B (en:Method)
ZA (1) ZA869078B (en:Method)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
CA2138998A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
CA2139000A1 (en) * 1992-06-23 1994-01-06 James W. Young Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
ID30432A (id) * 1999-01-20 2001-12-06 Knoll Pharmaceutical Co Metode untuk membantu menghentikan merokok
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
WO2000056306A1 (en) * 1999-03-19 2000-09-28 Knoll Gmbh Treatment of osteoarthritis
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
HK1044462B (en) * 1999-03-19 2006-03-03 Abbott Gmbh & Co. Kg Use of sibutramine or its derivative for the treatment of sleep disorders
AU3760600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
US6433020B1 (en) 1999-03-19 2002-08-13 Knoll Pharmaceutical Company Treatment of cardiovascular disease
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
EP1171106A1 (en) * 1999-03-19 2002-01-16 Knoll GmbH Treatment of certain cancers associated with weight gain
WO2000056321A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
AU3896900A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pain
MXPA01009468A (es) 1999-03-19 2004-03-19 Knoll Gmbh Tratamiento de hipertension pulmonar.
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
DE60334787D1 (de) * 2002-03-12 2010-12-16 Merck Sharp & Dohme Substituierte amide
WO2004030663A1 (en) * 2002-10-05 2004-04-15 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
EP1846359A4 (en) 2005-01-06 2010-03-31 Cj Cheiljedang Corp INORGANIC ACID SALTS OF SIBUTRAMINE
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
EP1912968A1 (en) * 2005-08-04 2008-04-23 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
WO2007034910A1 (ja) * 2005-09-22 2007-03-29 Eisai R & D Management Co., Ltd. 過食症及び過食症に伴ううつ病の治療用医薬組成物
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
RS20080371A (en) * 2006-02-23 2009-07-15 Pfizer Limited, Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX2009002781A (es) * 2006-09-15 2009-03-30 Reviva Pharmaceuticals Inc Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
AU2007323193A1 (en) * 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as Stearoyl CoA Desaturase inhibitors
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
CN102171206B (zh) * 2008-08-06 2014-06-25 辉瑞股份有限公司 作为mc4激动剂的二氮杂环庚烷和二氮杂环辛烷
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
SG186275A1 (en) 2010-07-06 2013-01-30 Astrazeneca Ab Therapeutic agents 976
AU2011326871B2 (en) 2010-11-04 2015-02-12 Albireo Ab IBAT inhibitors for the treatment of liver diseases
DK2637646T3 (en) 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
EP2890370B1 (en) 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
DE3674570D1 (de) 1990-10-31
IL80934A (en) 1990-07-26
NO865093D0 (no) 1986-12-16
KR940008913B1 (ko) 1994-09-28
CS930586A2 (en) 1988-02-15
SU1443796A3 (ru) 1988-12-07
CS259545B2 (en) 1988-10-14
HUT45964A (en) 1988-09-28
EP0230742A1 (en) 1987-08-05
FI865030A0 (fi) 1986-12-10
EG17770A (en) 1991-03-30
ZA869078B (en) 1987-07-29
NZ218578A (en) 1989-04-26
UA7206A1 (uk) 1995-06-30
LU90865I2 (fr) 2002-02-18
DK585786A (da) 1987-06-18
ES2018163B3 (es) 1991-04-01
FI865030L (fi) 1987-06-18
AU6644286A (en) 1987-06-18
NO165540C (no) 1991-02-27
NL300065I1 (nl) 2001-12-01
DD263050A5 (de) 1988-12-21
US5068440A (en) 1991-11-26
IE863102L (en) 1987-06-17
YU205086A (en) 1987-12-31
NO2005022I1 (no) 2005-10-03
EP0230742B1 (en) 1990-09-26
GR3001069T3 (en) 1992-03-20
FI90413B (fi) 1993-10-29
YU46033B (sh) 1992-12-21
ES2018163T4 (es) 2012-06-14
JPH0144176B2 (en:Method) 1989-09-26
JPS62155240A (ja) 1987-07-10
CA1266278A (en) 1990-02-27
DK170770B1 (da) 1996-01-15
PT83958A (en) 1987-01-01
ATE56942T1 (de) 1990-10-15
NO165540B (no) 1990-11-19
PH22481A (en) 1988-09-12
KR870005961A (ko) 1987-07-08
PL149519B1 (en) 1990-02-28
CN86108547A (zh) 1987-08-19
PT83958B (pt) 1989-05-12
PL263020A1 (en) 1988-05-12
MX4684A (es) 1993-12-01
HU201901B (en) 1991-01-28
GB8531071D0 (en) 1986-01-29
US4929629A (en) 1990-05-29
IE59429B1 (en) 1994-02-23
DK585786D0 (da) 1986-12-05
AU601167B2 (en) 1990-09-06
NO865093L (no) 1987-06-18
CN1016245B (zh) 1992-04-15
FI90413C (fi) 1994-02-10
GEP19970812B (en) 1997-02-10

Similar Documents

Publication Publication Date Title
AU549439B2 (en:Method)
IN163318B (en:Method)
AU4708385A (en:Method)
BA96126A (en:Method)
IN163607B (en:Method)
AU3954685A (en:Method)
BG44810A1 (en:Method)
BG44907A1 (en:Method)
BE901679A (en:Method)
BE905108A (en:Method)
BG39572A1 (en:Method)
BG40852A1 (en:Method)
BG44563A1 (en:Method)
BG44571A1 (en:Method)
BG44572A1 (en:Method)
BG44581A1 (en:Method)
BG44609A1 (en:Method)
BG44643A1 (en:Method)
BG44654A1 (en:Method)
BG44657A1 (en:Method)
BG44660A1 (en:Method)
BG44667A1 (en:Method)
BG44671A1 (en:Method)
BG44792A1 (en:Method)
BE901481A (en:Method)